

CURRICULUM VITAE

MONICA MONTOPOLI

Name and surname: Monica Montopoli

Place and Date of Birth:: Venezia - 06.02.1974

Nationality: Italian

Work address Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Largo E. Meneghetti 2, 35131 Padova, Italy.

Telephone number (work): +39 049 8275076

Fax number (work): +39 049 8275093

E-mail address: monica.montopoli@unipd.it

EDUCATION and PROFESSIONAL EXPERIENCE

2019-present Associate professor of Pharmacology (BIO/14), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy

2018-present Associate Investigator Fondazione di Ricerca Biomedica Avanzata-VIMM (Istituto Veneto di Medicina Molecolare) via Orus 2, Padova

2008-2019 Assistant professor of Pharmacology (BIO/14), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy.

2008 Postdoctoral fellowship from Department of Pharmacology and Anaesthesiology, University of Padova, "Sostanze di origine naturale per la sintesi di nuovi farmaci: attività farmacologica e approccio analitico multivariato per nuove strategie terapeutiche nella cura del cancro". prof. E. Ragazzi.

2007 Postdoctoral fellowship "Planning and performance of experiments on stress and rescue" Telethon Grant GGP06233 "Pathogenic mechanisms for degeneration of retinal ganglion cells in mitochondrial optic neuropathies".

2007 Ph.D. in "Molecular and cellular pharmacology" international collaboration with University of Padova, Leopold-Franzens Universitat, Innsbruck e Albert-Ludwigs Universitat, Freiburg.

Doctoral dissertation "Effect of natural and semisynthetic phenols and nuclear magnetic resonance approach in human ovarian cancer cell lines".

2003 Degree in Chimica e Tecnologia Farmaceutiche, Facoltà di Farmacia, University of Padova. "Studies on U2OS cancer cell lines wt and resistant on CDDP: natural phenol compounds activity and ¹H-NMR analysis"

Current research interests

Cellular and molecular pharmacology.

- 1). Metabolomic profile and mitochondrial function of tumor cell :mechanisms of anti-cancer drug action/toxicity and resistance
- 2) Chemioprevention strategies and cell cycle-protein regulators (cyclin, cdks etc.), apoptosis, transcription factors (NFkb, b-catenin),
- 3).Oxidative stress-mediated injury in cell models of neurodegenerative/genetic disorders and pharmacological rescue.

Research Grants:

2018 PI project PRID: "Molecular mechanisms involved in musculoskeletal disorders in oncological patients treated with tamoxifen to develop promising treatment to prevent disability and improve quality of life"

PI contract : "Pharmacological activity of d-methadone in cybrid cells model" Relmada USA

PI contract: "Antiflammatory activity of ProstaPlant" Schwabe Pharma Italia

2017 PI contract : Studi di effetti di Biflofen sul mantenimento della barriera epiteliale

intestinale Lemnia

PI contract: Studio sperimentale degli effetti di Colikind gocce sulla modulazione della produzione di citochine in un modello di epitelio intestinale Schwabe Pharma Italia

PI: Accordo Quadro con le aziende CEBIS International SAGL e AUDIT & GOVERNANCE GmbH

2016 PI contract- "Studi di inibizione della senescenza dell'estratto di S. Haenkei" IBSA INSTITUT, Svizzera

PI-contract: Attività di Colikind in un modello *in vitro* di epitelio intestinale. Ditta Loacker Remedia

PI -contract Studio di attività farmacologica di prodotti naturali in modelli di infiammazione intestinale e bronchiale" Università degli studi di Siena

2015 PI Contributo liberale di Ricerca "Travel Forum di Lugano " IBSA INSTITUT BIOCHIMIQUE

2013 PI -Contract: "Attività antiossidante e antiinfiammatoria di estratti di curcuma in un modello cellulare di epitelio intestinale". Ditta ECOBASE GmbH, Austria

2012 PI -PRAT : "Study of cisplatin resistance using trans-mitochondrial hybrids of cancer cells".

PI -MURST: "Riprogrammazione metabolica in modelli cellulari di patologia: identificazione di target farmacologici"

2011 PI -MURST: "Stress ossidativo e riprogrammazione metabolica: identificazione di target farmacologici"

2011-12 PI -Contributo di Liberalità: Studio dell'attività di sostanze di origine naturale in modelli sperimentali di patologie degenerative e infiammatorie, per individuare composti utili a prevenire e/o rallentare il danno cellulare indotto dallo stress ossidativo. Ditta EOS, TV, Italy

2010 PI -MURST: "Attività farmacologica di fenoli di origine naturale e di sintesi in modelli cellulari di stress ossidativo"

Collaboration in research founded grants

2019 Collaborator AIRC IG "Development of combination of pro-senescence and senolytic compounds for prostate cancer therapy" (PI prof. A. Alimonti)

2018 Collaborator Development of gerosuppressants and senolytic compounds for the treatment of aging and aging-related disorders (PI: Prof. Andrea Alimonti)

Collaborator Stars Grant University of Padova project entitled : "Featuring a new class of Interface Regulators: the Mitochondria-ER Spacers" Acronym: FIRMESs (PI dr Giacomello)

2015 Collaborator PRAT-University of Padova project entitled "Search for natural molecules to counteract cancer metabolic reprogramming" (PI prof. Carrara).

2014 Collaborator: Young Grant on Pediatric Research . “The neuronal role of lipids: from molecular function of genes to identification of biomarker in juvenile spastic paraplegia forms”.

2012: Collaborator: Grant of The United Mitochondrial Disease Foundation, USA. : “Estrogen mediated regulation of mitochondrial biogenesis and functions: possible therapeutic implications for Leber’s hereditary optic neuropathy”. Collaborator -PRAT Responsabile Prof.ssa Caparrotta, titolo: “Stress ossidativo e riprogrammazione metabolica”: nuovi target farmacologici in modelli cellulari di patologia” 2008-09: Collaborator MURST: “Sistema cardiovascolare: studio di molecole di origine naturale e di sintesi” Responsabile Prof.ssa Caparrotta, 2006-09 Collaborator -TELETHON – Grant GGP06233: “Pathogenic mechanisms for degeneration of retinal ganglion cells in mitochondrial optic neuropathies.” Planning and performance of experiments on stress and rescue. 2005-07 Collaborator - Ricerca Sanitaria Finalizzata Regione Veneto “Strategie di prevenzione e trattamento del danno ossidativo in modelli cellulari di malattia neurodegenerativa”. 2004 – Collaborator - Progetto di ricerca Padova Ricerche – Madaus: “Effetti di escina in cellule endoteliali in ipossia”.

Research Collaborations:

Chemotherapy resistance and Cancer metabolism: -Cancer Cell Unit Hutchison/MRC Research Centre Cambridge UK, IOR/IOSI Bellinzona – Switzerland- Beth Israel Deaconess Medical Center and Harvard Medical School , Department of Chemical Sciences, Biomedical Sciences University of Padua

Pharmacological targets in neurological diseases:-IRCCS “E. Medea”, “La nostra Famiglia” Conegliano (TV) -Istituto Italiano di Tecnologia Genova (IIT) -Department of Neurological Sciences, University of Bologna, , Bologna, Italy- -Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Italy

Teaching

Post Lauream

2019-present: Director of Corso di alta formazione in Micoterapia : aspetti farmacotossicologici dei funghi medicinali (University of Padova)

2017-present: Director of Corso di alta formazione in Fitoterapia clinica (University of Padova)

2014-present: Professor of Master I and II level of Fitoterapia University of Siena

Master degree

2019-present : “Pharmacology” Fisioterapia (Venice/Padova/Conegliano) University of Padova; “Tossicology” Scienze Farmaceutiche Applicate

2017- present: “Pharmacology” Scienze infermieristiche (Treviso) University of Padova

2014-present: “Pharmacology” Fisioterapia (Venice) University of Padova

2013-present “Preclinical and clinical studies of new drugs” Chimica e Tecnologia Farmaceutiche, University of Padova

2010-2014t: Experimental Pharmacology Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Padova

2008 – 2010 “Methods in pharmacology and toxicology” Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Padova

2007 – 2008 Laboratory assistance in “Methods in pharmacology” CLS in Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Padova

2004 – 2006 Tutor Junior, Faculty of Pharmacy, University of Padova

Mentoring and research training:

Post doc supervisor

- Supervisor of Dr. Catanzaro Daniela. Post-doctoral fellow at the Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Padova, Italy (03/ 2013-04/ 2014).

- Co-supervisor Post-doctoral fellow at the Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Padova, Italy (04/ 2014-03/ 2016). PI: E. Ragazzi: "Lipidomic/metabolomic approach to molecular mechanisms of platinum resistance in cancer cells".

PhD Student supervisor

-Supervisor of Veronica Cocetta (XXX cycle), Tatiana Trevisan. (XXVIII cycle; January 2013-2016) and Supervisor of Caterina Vianello (XXIX cycle; January 2014-2017). Doctoral school on "Pharmacological Sciences".

Final dissertation degree supervisor :

2004-2011 co-tutor of 18 student; 2011-present tutor of 14 student

Member Society

Full Member Società Italiana di Farmacologia (SIF)

Full Member and *Board of Directors* of Società Italiana di Fitoterapia (SiFit)

International Society of Cancer Metabolism (ISCaM)

Full Member Società Italiana di Citometria (GIC)

Scientific Committee and organization

2020

-IX° International SYRP: S.I.Fit. Young Researchers Project "Experimental models for the study of natural products" Parma, 22-24 May 2020- Scientific Committee and moderator

-METABOLISM MEETS FUNCTION 2020: The Multifaced Role of Metabolism in Cancer

A journey into the functional significance of the cellular metabolic programs

Florence, 20 July, 2020 Lecture Hall "AULA MAGNA" Complesso Didattico Morgagni; University of Florence Scientific Committee and organization.

2019

- VIII° International SYRP: S.I.Fit. Young Researchers Project "Experimental models for the study of natural products" Imola, 14 January 2019- Scientific Committee and moderator

-METABOLISM MEETS FUNCTION 2019

A journey into the functional significance of the cellular metabolic programs

Torino, 19 July, 2019 Molecular Biotechnology Center; University of Torino Scientific Committee and organization.

2018

- "Pharmacological insights of altered lipid metabolism in oncological, neurological, cardiovascular, and hepatic diseases". Department of Pharmaceutical and Pharmacological Sciences University of Padova, 5 December 2018 - Scientific Committee and organization.

-METABOLISM MEETS FUNCTION

A journey into the functional significance of the cellular metabolic programs

Bari, 19-20th July, 2018. Scientific Committee and organization.

2017

- **V° International SYRP: S.I.Fit. Young Researchers Project** San Marino, 20 November 2017- Scientific Committee and organization.

- **ISCaM2017 - 4th Annual Meeting - Cancer Metabolism** Thursday, 19 October 2017 to Saturday, 21 October 2017. Scientific Board

- **International Meeting – “Recent advances in cancer therapy”** Palazzo del Bo University of Padova , 10 October 2017-Scientific Committee and organization.

- **International Workshop- “New pharmacological approaches in oncology”**, Department of Pharmaceutical and Pharmacological Sciences University of Padova, 7 March 2017 - Scientific Committee and organization.

2016

-**International workshop-Fostering innovation Towards Start-Up DSF**, Department of Pharmaceutical and Pharmacological Sciences University of Padova in collaboration with UCL (London), 8 June 2016 - Scientific Committee

-**IV° Incontro SYRP: S.I.Fit. Young Researchers Project** Padova, 19 dicembre 2016- Scientific Committee and organization.

EDITORIAL AND RELATED ACTIVITIES

Guest editor : Frontiers

Ad Hoc Reviewer for journals

Oncotarget, Journal of ovarian cancer, Journal of Functional Foods, Journal of Pharmacy and Pharmacology, Cell Death & Disease, Natural product communication, Plosone.

PUBLICATIONS

1. Desbats M., Giacomini I., Galletti-Prayer T., **Montopoli M** . Metabolic plasticity in chemotherapy resistance,.Fronters Oncology DOI: 10.3389/fonc.2020.00281
2. Giacomini I, Ragazzi E, Pasut G., **Montopoli M** The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance. Int J Mol Sci 2020 Jan 31;21(3). Epub 2020 Jan 31.
3. Cocetta V, Ragazzi E, **Montopoli M** Links between cancer metabolism and cisplatin resistance International Review of Cell and Molecular Biology *in press*
4. Cocetta V, Ragazzi E, **Montopoli M** .Mitochondrial Involvement in Cisplatin Resistance Int J Mol Sci. 2019 Jul 10;20(14). pii: E3384. doi: 10.3390/ijms20143384.
5. Borgonetti V., Governa P, **Montopoli M**, Biagi.M Cannabis sativa L. Constituents and Their Role in Neuroinflammation Current Bioactive Compounds, *in press*
6. Governa P, Marchi M, Cocetta V, De Leo B, Saunders PTK, Catanzaro D, Miraldi E, **Montopoli M**, Biagi M. Effects of Boswellia Serrata Roxb. and Curcuma longa L. in an In Vitro Intestinal Inflammation Model Using Immune Cells and Caco-2. Pharmaceuticals (Basel). 2018 Nov 20
7. Cocetta V, Catanzaro D, Borgonetti V, Ragazzi E, Giron MC, Governa P, Carnevali I, Biagi M, **Montopoli M**. A fixed combination of probiotics and herbal extracts attenuates intestinal barrier dysfunction from inflammatory stress in an in vitro model using Caco-2 cells. Recent Pat Food Nutr Agric. 2018 Aug 8.
8. Fumagalli G, Giorgi G, Vágvölgyi M, Colombo E, Christodoulou MS, Collico V, Prosperi D, Dosio F, Hunyadi A, **Montopoli M**, Hyeraci M, Silvani A, Lesma G, Via LD, Passarella D. Heteronanoparticles by Self-Assembly of Ecdysteroid and Doxorubicin Conjugates To Overcome Cancer Resistance. ACS Med Chem Lett. 2018 Apr 17;9(5):468-471. doi: 10.1021/acsmchemlett.8b00078.
9. Catanzaro D , Nicolosi S, Cocetta V , Salvalaio M , Pagetta A, Ragazzi E, **Montopoli M***, Pasut G*. Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells. Oncotarget, *in press* co-corresponding authors*
10. Strobbe D, Caporali L, Iommarini L, Maresca A, **Montopoli M**, Martinuzzi A, Achilli A, Olivieri A, Torroni A, Carelli V, Ghelli A. Haplogroup J mitogenomes are the most sensitive to the pesticide rotenone: Relevance for human diseases. Neurobiol Dis. 2018 Feb 24. pii: S0969-9961(18)30042-1.
11. Caporali L, Iommarini L, La Morgia C, Olivieri A, Achilli A, Maresca A, Valentino ML, Capristo M, Tagliavini F, Del Dotto V, Zanna C, Liguori R, Barboni P, Carbonelli M, Cocetta V, **Montopoli M**, Martinuzzi A, Cenacchi G, De Michele G, Testa F, Nesti A, Simonelli F, Porcelli AM, Torroni A, Carelli V. Peculiar combinations of individually non-pathogenic missense mitochondrial DNA variants cause low penetrance Leber's hereditary optic neuropathy. PLoS Genet. 2018 Feb 14;14(2):e1007210.

12. Jingjing Chen, Ilaria Guccini, Diletta Di Mitri, Daniela Brina, Ajinkya Revandkar, Emiliano Pasquini¹, Abdullah Alajati¹, Sandra Pinton, Marco Losa, Manuela Sarti, Gianluca Civenni, Carlo V. Catapano, Jacopo Sgrignani, Andrea Cavalli, Rocco D'Antuono, John M. Asara, Andrea Morandi, Paola Chiarugi, Sara Crotti, Marco Agostini, **Monica Montopoli**, Ionica Masgras, Andrea Rasola, Ramon Garcia-Escudero, Nicolas Delaleu, Andrea Rinaldi, Francesco Bertoni, Johann de Bono, Arkaitz Carracedo & Andrea Alimonti . Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. *Nature genetics, Nat Genet.* 2018 Feb;50(2):219-228.
13. Catanzaro D, Gabbia D, Cocetta V, Biagi M, Ragazzi E, **Montopoli M***, Carrara M. Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression. *Fitoterapia.* 2017 Oct 12. *corresponding authors*
14. Buriani A, Fortinguerra S, Sorrenti V, Dall'Acqua S, Innocenti G, **Montopoli M**, Gabbia D, Carrara M. Human Adenocarcinoma Cell Line Sensitivity to Essential Oil Phytocomplexes from Pistacia Species: a Multivariate Approach. *Molecules.* 2017 Aug 11;22(8). pii: E1336. doi: 10.3390/molecules22081336.
15. Caputi V, Marsilio I, Filpa V, Cerantola S, Orso G, Bistoletti M, Paccagnella N, De Martin S, **Montopoli M**, Dall'Acqua S, Crema F, Di Gangi IM, Galuppini F, Lante I, Bogialli S, Rugge M, Debetto P, Giaroni C, Giron MC. Antibiotic-induced dysbiosis of the microbiota impairs gut neuromuscular function in juvenile mice. *Br J Pharmacol.* 2017 Oct;174(20):3623-3639. doi: 10.1111/bph.13965. Epub 2017 Aug 30.
16. Matic I, Revandkar A, Chen J, Bisio A, Dall'Acqua S, Cocetta V, Brun P, Mancino G, Milanese M, Mattei M, **Montopoli M**, Alimonti A. Identification of *Salvia haenkei* as gerosuppressant agent by using an integrated senescence-screening assay. *Aging (Albany NY).* 2016 Dec 1;8(12):3223-3240. doi: 10.18632/aging.101076.
17. Bertin R, Chen Z, Marin R, Donati M, Feltrinelli A, **Montopoli M**, Zambon S, Manzato E, Frolidi G. Activity of myricetin and other plant-derived polyhydroxyl compounds in human LDL and human vascular endothelial cells against oxidative stress. *Biomed Pharmacother.* 2016 Aug;82:472-8. doi: 10.1016/j.biopha.2016.05.019. Epub 2016 Jun 1.
18. Catanzaro D, Filippini R, Vianello C, Carrara M, Ragazzi E, **Montopoli M**. Chlorogenic Acid Interaction with Cisplatin and Oxaliplatin: Studies in Cervical Carcinoma Cells. *Natural Product Communication.* (2016) 11(4): 431-568. 2014
19. Dall'Acqua S, Catanzaro D, Cocetta V, Igl N, Ragazzi E, Giron MC, Cecconello L, **Montopoli M**. Protective effects of ψ taraxasterol 3-O-myristate and arnidiol 3-O-myristate isolated from *Calendula officinalis* on epithelial intestinal barrier. *Fitoterapia.* (2016) 109:230–235. 2014
20. Pisano A, Preziuso C, Iommarini L, Perli E, Grazioli P, Campese AF, Maresca A, **Montopoli M**, Masuelli L, Sadun AA, d'Amati G, Carelli V, Ghelli A, Giordano C. Targeting estrogen receptor β as preventive therapeutic strategy for Leber's Hereditary Optic Neuropathy. *Hum Mol Genet.* 2015 Sep 26. pii: ddv396.
21. Catanzaro D, Gaude E, Orso G, Giordano C, Pisano A, Guzzo G, Rasola A, Ragazzi E, Caparrotta L, Frezza C, **Montopoli M**. Inhibition of Glucose-6-phosphate dehydrogenase sensitizes cisplatin resistant cells to death. *Oncotarget.* 2015 Aug 17.

22. Catanzaro D, Ragazzi E, Vianello C, Caparrotta L and **Montopoli M**. Effect of quercetin on cell cycle and cyclin expression in ovarian and osteosarcoma wild type and cisplatin-resistant cell lines. *Natural prod comm., in press*
23. Catanzaro D, Rancan S, Orso G, Dall'Acqua S, Brun P, Giron MC, Carrara M, Castagliuolo I, Ragazzi E, Caparrotta L, **Montopoli M**. Attività antinfiammatoria e antiossidante di *Boswellia serrata* in un modello di epitelio intestinale *in vitro*. *Piante medicinali* (ISSN:1825-5086). 2015, 14(1): 31-2.
24. Catanzaro D, Rancan S, Orso G, Dall'Acqua S, Brun P, Giron MC, Carrara M, Castagliuolo I, Ragazzi E, Caparrotta L, **Montopoli M**. *Boswellia serrata* Preserves Intestinal Epithelial Barrier from Oxidative and Inflammatory Damage. *PLoS ONE*. 2015 10(5): e0125375
25. Catanzaro D, Vianello C, Ragazzi E, Caparrotta L, **Montopoli M**. Cell cycle control by natural phenols in Cisplatin-resistant cell lines. *Natural prod comm.* 2014 9;(10):1465-1468.
26. Licciardi M, Pasut G, Amato G, Scialabba C, Mero A, **Montopoli M**, Cavallaro G, Schiavon O, Giammona G. PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery. *Eur J Pharm Biopharm*. 2013 May;84(1):21-8
27. **Montopoli M**, Bertin R, Chen Z, Bolcato J, Caparrotta L, Froidi G. Croton lechleri sap and isolated alkaloid taspine exhibit inhibition against human melanoma SK23 and colon cancer HT29 cell lines. *J Ethnopharmacol*. 2012 Oct 30.
28. Nagy EM, Sitran S, **Montopoli M**, Favaro M, Marchiò L, Caparrotta L, Fregona D. Zinc(II) complexes with dithiocarbamate derivatives: Structural characterisation and biological assays on cancerous cell lines. *J Inorg Biochem*. 2012 Sep 13;117C:131-139.
29. Perli E, Giordano C, Tuppen HA, **Montopoli M**, Montanari A, Orlandi M, Pisano A, Catanzaro D, Caparrotta L, Musumeci B, Autore C, Morea V, Di Micco P, Campese AF, Leopizzi M, Gallo P, Francisci S, Frontali L, Taylor RW, d'Amati G. Isoleucyl-tRNA synthetase levels modulate the penetrance of a homoplasmic m.4277T>C mitochondrial tRNA(Ile) mutation causing hypertrophic cardiomyopathy. *Hum Mol Genet*. 2012 Jan 1;21(1):85-100.
30. Froidi G, Bertin R, Dorigo P, **Montopoli M**, Caparrotta L. Endothelium-independent vasorelaxation by ticlopidine and clopidogrel in rat caudal artery. *J Pharm Pharmacol*. 2011;63:1056-62.
31. **Montopoli M**, Bellanda M, Lonardoni F, Ragazzi E, Dorigo P, Froidi G, Mammi S, Caparrotta L. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin. *Curr Cancer Drug Targets*. 2011;11:226-35.
32. Giordano C, **Montopoli M**, Perli E, Orlandi M, Fantin M, Ross-Cisneros FN, Caparrotta L, Martinuzzi A, Ragazzi E, Ghelli A, Sadun AA, d'Amati G, Carelli V. Oestrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy. *Brain*. 2011 ;134:220-34.

33. Frolidi G, Zagotto G, Filippini R, **Montopoli M**, Dorigo P, Caparrotta L. Activity of sap from *Croton lechleri* on rat vascular and gastric smooth muscles. *Phytomedicine*. 2009 ;16:768-75.
34. Albertin G, Guidolin D, Sorato E, Spinazzi R, Mascarin A, Oselladore B, **Montopoli M**, Antonello M, Ribatti D. Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations. *Regul Pept*. 2009;157:64-71.
35. **Montopoli M**, Ragazzi E, Frolidi G, Caparrotta L. Cell cycle inhibition and apoptosis induced by curcumin combined with cisplatin or oxaliplatin in human ovarian carcinoma cell lines. *Cell Proliferation Cell Prolif*. 2009;42:195-206.
36. Tramentozzi E, Pagetta A, Frasson M, Brunati A, **Montopoli M**, Finotti P. Angiogenic transforming capacity of IgG purified from plasma of type 1 diabetic subjects. *Journal of Cellular and Molecular Medicine* 2009 Jul;13(7):1336-47
37. Cozza G, Gianoncelli A, **Montopoli M**, Caparrotta L, Meggio F, Pinna L A, Zagotto G, Moro S. Anthraquinone moiety as a versatile Ser/Thr kinase inhibitor scaffold: the protein kinase CK1 delta (CK1 δ) as a new biological target. *Bioorganic & Medicinal Chemistry Letters*. 2008;18:5672-5.
38. Giovagnini L, Sitran S, **Montopoli M**, Caparrotta L, Corsini M, Rosani C, Zanella P, Dou QP, Fregona D. Chemical and biological profiles of novel copper (II) complexes containing S-donor ligand for the treatment of cancer. *Inorganic Chemistry*. 2008 ;47:6336-43.
39. Frolidi G, **Montopoli M**, Zanetti M, Dorigo P, Caparrotta L. 5-HT_{1B} receptor subtype and ageing in rat resistance vessels. *Pharmacology* 2008; 81: 70-8.
40. Frolidi G, Tissi M, Montopoli M. Cinetica dell'alcol etilico: fattori di variabilità in relazione agli effetti benefici e tossici. *Alcologia* 2008, 2: 55-63.
41. Sala G, Trombin F, Beretta S, Tremolizzo L, Presutto P, **Montopoli M**, Fantin M, Martinuzzi A, Carelli V, Ferrarese C. Antioxidants partially restore glutamate transport defect in Leber Hereditary Optic Neuropathy cybrids. *Journal of Neuroscience Research* 2008; 86:3331-7.
42. Tramentozzi E, **Montopoli M**, Orso G, Pagetta A, Caparrotta L, Frasson M, Brunati AM, Finotti P. Glucose-regulated protein94 (Grp94) induces proliferation and differentiation of HUVECs by a cytokine-like mechanism involving the increased expression of both HSP90 and HSP70. Differences of effects for Grp94 in complexes with human IgG. *Molecular Immunology* 2008;45:3639-48.
43. **Montopoli M**, Frolidi G, Comelli MC, Prosdocimi M, Caparrotta L. Aescin protection of human vascular endothelial cells exposed to cobalt chloride mimicked-hypoxia and inflammatory stimuli. *Planta Medica* 2007, 73: 285-8.
44. Frolidi G, Galzignato G, Zanetti M, **Montopoli M**, Dorigo P, Caparrotta L. Are prostanoids related to positive inotropism by UTP and ATP ? *Pharmacology* 2005, 73: 140-5.

PROCEEDINGS

1. **Montopoli M**, Moro S, Cozza G, Zagotto G, Frolidi G, Ragazzi E, Caparrotta L. Inhibition of cell cycle and apoptosis in human cervix carcinoma cell lines induced by rhein, quercetin and plumbagin and in silico designed semisynthetic analogs. *Cytometry Part A* (2008), 73A: 61.
2. **Montopoli M**, Fantin M, Caparrotta L, Carelli V, Martinuzzi A. Response to metabolic stress in cybrids obtained from patients with Leber's hereditary optic neuropathy. *Biochimica et Biophysica acta-bioenergetics* (2008). vol. 1777, pp. S85-S85
3. Frolidi G, **Montopoli M**, Ragazzi E, Gaion RM, Caparrotta L, Dorigo P. Is in vitro vasorelaxation by ticlopidine related to P2Y12 receptors? *Purinergic signalling* (2006) 2: 242
4. **Montopoli M**, Ragazzi E, Caparrotta L, Frolidi G. Ticlopidine and clopidogrel affect vascular smooth muscle cell proliferation in culture. *Purinergic signalling* (2006) 2: 217
5. **Montopoli M**, Bellanda M, Mammi S, Moro S, Zagotto G, Frolidi G, Ragazzi E, Caparrotta L. Effects of natural semisynthetic and synthetic phenolics and nuclear magnetic resonance on human ovarian cancer cell lines. *Tumori* (2005), 4(4): 68.

:

Oral presentation

1. **Montopoli M: (Invited speaker)** Cancer cell metabolism and new pharmacological targets in cisplatin resistance, 3° Annual meeting of the international society of cancer metabolism, ISCaM2016, Bruxelles-Belgium 26-29 October 2016
2. Cocetta V., Carnevali I., **Montopoli M**. Colikind as promising approach to preserve barrier intestinal: studies in *in vitro* model. XXIV Congresso Nazionale di Fitoterapia, 28 May 2016 (Arezzo).
3. Catanzaro D., Caparrotta L., Martinuzzi A., Giordano C., Carelli V., Ragazzi E., **Montopoli M**. Genistein pharmacological activity in Leber Hereditary Optic neuropathies (LHON): study of molecular mechanism in cybrid cell models XIV Congresso della Societa' Italiana di Fitochimica 2015, Padova, Italy, 10-12 June 2015
4. Catanzaro D, Rancan S, Dall'Acqua S, Brun P, Castagliuolo I, Carrara M, Giron MC, Ragazzi E, Caparrotta L, **Montopoli M**. Attività antinfiammatoria e antiossidante di *Boswellia serrata* in un modello di epitelio intestinale *in vitro* XXIII Congresso Nazionale di Fitoterapia Rimini, Italy, 15 - 17 May 2015

Poster presentation

1. Cocetta V, Catanzaro D., Gabbia D, Eugenio Ragazzi E, Biagi M, Carrara M, **Montopoli M**. SILYBIN GLYCOLYSIS INHIBITOR AS PROMISING AGENT IN CHEMOTHERAPY VI SYRP: S.I.Fit. YOUNG RESEARCHERS PROJECT –Republic of San Marino, 20 November 2017

2. Cocetta V, Catanzaro D., Vianello C, Ragazzi E., **Montopoli M.** ROLE OF MITOCHONDRIA IN CISPLATIN-RESISTANCE PHENOMENA 38° congresso SIF – Rimini 25-28 ottobre 2017
3. Cocetta V, Vianello C, Catanzaro D, Ragazzi E, Scorrano L, **Montopoli M.** IMBALANCE OF MITOCHONDRIAL “SHAPING PROTEINS” AND CISPLATIN RESISTANCE iSCaM2017 - 4th Annual Meeting - Cancer Metabolism 19-21 October 2017 - BERTINORO
4. Cocetta V., Vianello C. , Catanzaro D. , Ragazzi E. , Montopoli M. MITOCHONDRIAL ALTERATIONS INVOLVED IN CISPLATIN RESISTANCE PHENOMENA Padua-Mit-Innsbruck “Mitochondrial Conference” PADOVA, 13-14 SETTEMBRE 2017
5. Cocetta V., Catanzaro D., Stefano Dall’Acqua S, Ragazzi E, **Montopoli M** Cannabis Sativa modulates epithelial permeability in an in vitro intestinal inflammation model. XXV Congresso Nazionale di Fitoterapia- SYRP: S.I.FIT. YOUNG RESEARCHERS PROJECT Arezzo, 26th May
6. Vianello C., Catanzaro D., Cocetta V., Ragazzi E., **Montopoli M.** Mitochondrial remodeling involved in cisplatin resistance. 19° Seminario SIF, 20-22 September 2016 (Rimini)
7. Catanzaro D, Gaude E, Orso G, Guzzo G, Rasola A, Ragazzi E, Caparrotta L, Carrara M, Frezza C, **Montopoli M.** Targeting Glucose-6-phosphate dehydrogenase to overcome cisplatin resistance in ovarian cancer. Translational research in cancer cell metabolism-EMBO Conference. 4-6 October 2016 (Bilbao).
8. Vianello C, Brown K.K, Catanzaro D, **Montopoli M**, Toker A. Highlighting glucose and glutamine metabolism in breast cancer and their role in cisplatin chemoresistance. Translational research in cancer cell metabolism-EMBO Conference. 4-6 October 2016 (Bilbao).
9. Catanzaro D, Gaude E, Orso G, Guzzo G, Rasola A, Ragazzi E, Caparrotta L, Frezza C, **Montopoli M.** Inhibition of pentose phosphate pathway as novel approach to counteract cisplatin resistance. 58th Annual Meeting of the Italian Cancer Society. 5-8 September 2016 (Verona).
10. Catanzaro D, Gabbia D, Cocetta V, Ragazzi E, **Montopoli M**, Carrara M. Natural polyphenols as chemosensitizer: studies in resistant cancer cells. 58th Annual Meeting of the Italian Cancer Society. 5-8 September 2016 (Verona).
11. Catanzaro D., Gabbia D., Cocetta V., Ragazzi E., **Montopoli M.**, Carrara M. Natural polyphenols as chemosensitizer: studies in resistant cancer cells. 58th Annual Meeting of the Italian Cancer Society. 5-8 September 2016 (Verona)
12. Vianello C, Catanzaro D, Ragazzi E, Caparrotta L, **Montopoli M.** Mitochondrial network organization in cisplatin resistant cells 37° Congresso Nazionale della Società Italiana di Farmacologia I NUOVI ORIZZONTI DELLA RICERCA FARMACOLOGICA: TRA ETICA E SCIENZA. Naples, Italy, 27 - 30 October 2015
13. Catanzaro D., Gaude E., Orso G., Guzzo G., Rasola A., Ragazzi E., Caparrotta L., Frezza C., **Montopoli M.** Metabolic liabilities in cisplatin cancer resistant cells. Cancer and Metabolism conference, Cambridge, UK, 28-30 September, 2015

14. **Montopoli M**, Barattin M, Vianello C, Bellato F, Catanzaro D, Bersani S, Stefano Salmaso S. Anionic Liposomes For Enhanced Metformin Delivery To Cancer Cell Mitochondria 2nd ANNUAL MEETING OF THE INTERNATIONAL SOCIETY OF CANCER METABOLISM 16-19 September 2015 Venice - Italy
15. Catanzaro D, Bellanda M, Ragazzi E, Vianello C, Mammi S, Caparrotta L, Caliceti P, **Montopoli M**. Cisplatin resistance and cell metabolism : ¹H-NMR approach to profile metabolites in living ovarian carcinoma cells 2nd ANNUAL MEETING OF THE INTERNATIONAL SOCIETY OF CANCER METABOLISM 16-19 September 2015 Venice - Italy
16. Vianello C, Catanzaro D, Ragazzi E, Caparrotta L, **Montopoli M**. Cisplatin-resistant cells exert the glycolysis dependent phenotype 2nd ANNUAL MEETING OF THE INTERNATIONAL SOCIETY OF CANCER METABOLISM 16-19 September 2015 Venice - Italy
17. Catanzaro D, Orso G, Giordano C, Vianello C, Ragazzi E, Caparrotta L, Frezza C, **Montopoli M**. Use of transmitochondrial hybrids to investigate the influence of mtDNA mutations in cisplatin resistance. EACR-AACR-SIC 2015 Special Conference on Anticancer Drug Action and Drug Resistance from Cancer Biology to the Clinic. 20-23 June 2015. (Firenze).
18. Catanzaro D, Bellanda M, Ragazzi E, Vianello C, Mammi S, Caparrotta L, **Montopoli M**. ¹H-NMR to detect intracellular metabolites in living human ovarian cancer cell lines. EACR-AACR-SIC 2015 Special Conference on Anticancer Drug Action and Drug Resistance from Cancer Biology to the Clinic. 20-23 June 2015. (Firenze).
19. Vianello C, Catanzaro D, Ragazzi E, Caparrotta L, **Montopoli M**. Depletion of mitochondrial DNA modulates cellular sensitivity to cisplatin. EACR-AACR-SIC 2015 Special Conference on Anticancer Drug Action and Drug Resistance from Cancer Biology to the Clinic. 20-23 June 2015. (Firenze).
20. Montopoli M Catanzaro D, Rancan S, Dall'Acqua S, Brun P, Castagliuolo I, Giron MC, Carrara M, Caparrotta L, ,Ragazzi E. Antioxidant and anti-inflammatory activities of *Boswellia serrata* in epithelial intestinal cell line. XIV Congresso della Societa' Italiana di Fitochimica 2015, Padova, Italy, 10-12 June 2015
21. Catanzaro D, Orso G, Giordano C, Vianello C, Ragazzi E, Caparrotta L, Frezza C, **Montopoli M**. Transmitochondrial hybrids as model to investigate mitochondria involvement in cisplatin resistance. Translational advances in cancer cell signalling and metabolism-EMBO workshop. Bilbao, Spain 7-9 October 2014
22. Catanzaro D, Bellanda M, Ragazzi E, Vianello C, Mammi S, Caparrotta L, **Montopoli M**. ¹H- NMR approach to fingerprint metabolic profile of human cancer cell lines. Translational advances in cancer cell signalling and metabolism-EMBO workshop. Bilbao, Spain 7-9 October 2014
23. Vianello C, Catanzaro D, Ragazzi. E, Caparrotta L, **Montopoli M**. Impairment of mitochondrial oxidative metabolism in platinating drug resistance. Translational advances in cancer cell signalling and metabolism-EMBO workshop. Bilbao, Spain 7-9 October 2014

24. Vianello C, Catanzaro D, **Montopoli M.** Mitochondrial function in human cisplatin-resistant and sensitive cell lines. Seminario Nazionale in Farmacologia e Scienze Affini per Dottorandi, Assegnisti di Ricerca, Post-dottorandi e Specializzandi. Rimini, Italy 16-18 September 2014
25. Catanzaro D, Frezza C, Orso G, Bellanda M, Ragazzi E, Caparrotta L, **Montopoli M** Lipogenic phenotype of ovarian carcinoma cell lines resistant to cisplatin. *Membrane, Morphology and Function. FEBS/EMBO.* Fara San Martino, Italy 5–8 May 2014.
26. Catanzaro D, Rancan S, Dall'Acqua S, Brun P, Castagliuolo I, Giron MC, Frolidi G, Ragazzi E, Caparrotta L, **Montopoli M.** Boswellia serrata: antioxidant and anti-inflammatory activities in epithelial intestinal cells. *XXXIV° Congresso Nazionale della Società Italiana di Farmacologia.* Torino, Italy 23-26 October 2013.
27. Catanzaro D, **Montopoli M,** Bellanda M, Frezza C, Frolidi G, Ragazzi E, Caparrotta L. Rho0 cells and metabolomic approach to exploit mechanism of resistance to cisplatin in ovarian cancer cell lines. *XXXIV° Congresso Nazionale della Società Italiana di Farmacologia.* Torino, Italy 23-26 October 2013.
28. Chen Z. , Bertin R., Marin R., **Montopoli M.,** Frolidi G. Antioxidant properties of medicinal plants as potential antiatherosclerotic remedies: *in vitro* and *ex vivo* studies. *XXXIV° Congresso Nazionale della Società Italiana di Farmacologia.* Torino, Italy 23-26 October 2013.
29. Chen Z., Donati M., Mondin A., Bertin R., Miranda FM., **Montopoli M.,** Frolidi G. *In vitro* radical scavenging activity of essential oils from Brazilian medicinal plants: Croton zehntneri, Pterodon emarginatus and Schinopsis brasiliensis. *XXXIV° Congresso Nazionale della Società Italiana di Farmacologia.* Torino, Italy 23-26 October 2013.
30. Catanzaro D. **Montopoli M.,** Bellanda M., Ragazzi E., Frolidi G., Giordano C., Gaude E., Sciacovelli M., Frezza C., Caparrotta L. Insight into mitochondrial and metabolic asset of cisplatin ovarian cancer cells. *Cancer and Metabolism* 2013, Amsterdam, The Netherlands, 24-25 June 2013.
31. Catanzaro D. **Montopoli M.,** Bellanda M., Ragazzi E., Frolidi G., Mammi S., Caparrotta L. Molecular Mechanism of resistance to cisplatin: study of metabolism in ovarian cancer cells. XI ISPC, XI International symposium on platinum coordination compounds in cancer chemotherapy stem cells, DNA repair mechanisms, DNA-damaging agents. Verona, Italy, 11-14 October 2012
32. **Montopoli M.,** Catanzaro D., Bellanda M., Giordano C., Mammi S., Ragazzi E., Caparrotta L. Metabolic profile of cisplatin-resistant phenotype: studies in ovarian carcinoma cell lines. 22nd Biennial EACR (European Association for Cancer Research) Congress. Barcelona, Spain, 7-10 July 2012.
33. Martinuzzi A., **Montopoli M.,** Zanarella E., Fantin M., Rossetto M., De Nardo V., Carelli V., Ghelli A., Rugolo M., Daga A., Bresolin N. Strategie di prevenzione e trattamento del danno ossidativo in modelli cellulari di malattia neurodegenerativa. "Il Veneto per la Ricerca" La ricerca sanitaria promossa e sostenuta dalla regione Veneto. Venezia-Italy, 28 -29 June 2012.

34. **Montopoli M.**, Catanzaro D., Martinuzzi A., Pisano A., Caparrotta L., d'Amati G., Carelli V. Giordano C. Effects of genistein on Leber's hereditary optic neuropathy (LHON) mitochondrial metabolism. Euromit 8 European Meeting on Mitochondrial Pathology. Zaragoza- Spagna, 20- 23 June 2011.
35. **Montopoli M.**, Bellanda M., Ragazzi E., Catanzaro D., Frolidi G., Giordano C., Mammi S., Caparrotta L.. Mitochondria on cisplatin resistance: studies on ovarian cancer cells. In: 35° Congresso nazionale della Società Italiana di Farmacologia. Il Farmaco: dalla ricerca alla salute dell'uomo Bologna-Italy, 14-17 September 2011
36. **Montopoli M.**, Catanzaro D., Perli E., Ragazzi E., Frolidi G., Giordano C., Caparrotta L.. Oxidative stress and metabolic reprogramming: study of pharmacological targets in cellular models of mitochondrial disease. Il Farmaco: dalla ricerca alla salute dell'uomo Bologna-Italy, 14-17 September 2011
37. Bertin R., **Montopoli M.**, Solda L., Martanez-Vasquez M., Garca-Argaa A, Caparrotta L., Frolidi G. Pharmacological properties of Casimiroa spp. extracts and isolated phenolic compounds: vasorelaxation and antioxidant effects. Il Farmaco: dalla ricerca alla salute dell'uomo. Bologna-Italy, 14-17 September 2011
38. Giordano C, **Montopoli M**, Perli E, Orlandi M, Fantin M, Ross-Cisneros FN, Caparrotta L, Martinuzzi A, Ragazzi E, Ghelli A, Sadun AA, d'Amati G, Carelli V. Estrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy. In: XII International Congress on Neuromuscular disease. Naples, Italy 17-22 July 2010.
39. Perli E., Giordano C., Tuppen HA., Orlandi M., Autore C., Pisano A., Musumeci B., Taylor RW., **Montopoli M.**, d'Amati G. Phenotypic expression of homoplasmic mutations in mitochondrial tRNA genes: role of aminoacyl-tRNA synthetases. In: XII International Congress on Neuromuscular disease. Naples, Italy 17-22 July 2010.
40. **Montopoli M.**, Ragazzi E., Frolidi G., Dorigo P., Caparrotta L. Curcumin increases sensitività of resistant ovarian tumour cells to platinum drugs: apoptotic effects and cell cycle alterations. 34° Congresso Nazionale della Società Italiana di Farmacologia. Rimini, 14-17 October 2009
41. Frolidi G., **Montopoli M.**, Caparrotta L., Dorigo P. Studies in vitro of pharmacological properties of ecuadorian blood-red sap from croton lechleri. . 34° Congresso nazionale della Società Italiana di Farmacologia. Rimini, Palacongressi, 14-17 October 2009
42. **Montopoli M.**, Moro S. ,Cozza G.,Zagotto G.,Frolidi G.,Ragazzi E. and Caparrotta L.. *In vitro* antitumor properties of in silico designed semisynthetic phenol derivatives. *III Meeting Nuove prospettive in chimica farmaceutica* 13-14 Febbraio 2009, Ciocco Castelvecchio-Lucca, Italy
43. Tramentozzi E., Pagetta A., Frasson M., **Montopoli M**, Finotti P. Glucose-regulated protein94 (Grp94) forms stable complexes with human IgG that promote a strong angiogenic transformation of HUVECs by a cytokine-like mechanism. *X National Biotechnology Congress*, September 17-19, 2008 Perugia, Italy.
44. Tramentozzi E, Pagetta A, Frasson M, **Montopoli M**, Finotti P. Immune complexes of Glucose-regulated protein94 (Grp94) with IgG, present in the plasma of type 1

diabetic subjects, show strong angiogenic-transforming capacity on HUVECs. *33rd FEBS Congress and 11th IUBMB Conference: Biochemistry of Cell Regulation*, 28 June - 3 July 2008 Athens, Greece.

45. **Montopoli M**, Fantin M, Caparrotta L, Carelli V, Martinuzzi A. Development of flexible paradigm of oxidative stress to investigate the pathogenesis of mtDNA mutations in the cybrid system. *Euromit The seventh European Meeting on Mitochondrial Pathology*. June 11-14 2008, Stockholm. Sweden.
46. **Montopoli M**, Fantin M, Caparrotta L, Carelli V, Martinuzzi A. Response to metabolic stress in cybrids obtained from patients with Leber's hereditary optic neuropathy. *XV European Bioenergetic Conference*, July 19 - 24 2008, Trinity College Dublin, Ireland.
47. **Montopoli M**, Caparrotta L, Dorigo P, Frolidi G. Croton Lechleri sap inhibits in vitro proliferation of HT-29 human colon cancer cells. *2° Verona International Meeting on Foods, Phytotherapeutic Compounds and Health*, 29-30 settembre 2007, Verona.
48. Frolidi G, Caparrotta L, **Montopoli M**, Garcia-Argàez A, Munoz-Ocotero V, Martinez-Vásquez M. Azione farmacologia in vitro di casamiroa edulis in tessuti vascolari a resistenza. *XVI Congresso Italo-latinoamericano di Etnomedicina "Carlo L. Spegazzini"*, 4-8 Settembre 2007, La Plata (Argentina).
49. **Montopoli M**, Moro S, Cozza G, Zagotto G, Frolidi G, Ragazzi E, Caparrotta L. Natural and semisynthetic anthraquinones, flavonoids and naphthoquinones effects on cell cycle in human ovarian cancer. *XXXIII Congresso Nazionale della Società Italiana di Farmacologia*. 6-9 giugno 2007, Cagliari.
50. Tramentozzi E, Pagetta A, **Montopoli M**, Frasson M, Finotti P. Angiogenesi indotta dalla "heat shock protein Glucose-regulated protein 94 (GRP94) con meccanismo simile a quello di una citochina. *XXXIII Congresso Nazionale della Società Italiana di Farmacologia*. 6-9 giugno 2007, Cagliari (Italia).
51. Frolidi G, **Montopoli M**, Dorigo P, Caparrotta L. Direct effects of ticlopidine and clopidogrel on resistance vessel in vitro. *XXXIII Congresso Nazionale della Società Italiana di Farmacologia*, 6-9 giugno 2007, Cagliari.
52. Giovagnini L, Sitran S, Caparrotta L, **Montopoli M**, Fregona D. Copper(II)-based potential antitumour agents with S-donor chelating ligands. *6th Symposium on Pharmaco-Bio-Metallics*. 30 novembre -1 dicembre 2006, Napoli.
53. **Montopoli M**. Natural and semisynthetic phenolics and nuclear magnetic resonance in human ovarian cancer cell lines. *X Seminario Nazionale Dottorandi in Farmacologia ed affini*. 25-28 settembre 2006, Pontignano (Siena).
54. Bellanda M, **Montopoli M**, Lonardoni F, Caparrotta L, Mammi S. H-NMR reveals significantly different levels of glutathione in sensitive or spontaneously resistant to cisplatin cells from human ovarian cancer lines. *XXXVI National Congress on Magnetic Resonance*, 20-23 settembre 2006. Salerno.
55. Prosdocimi M, **Montopoli M**, Frolidi G, Comelli MC, Caparrotta L. Escina inibisce nelle cellule endoteliali umane l'effetto dell'ipossia e dell'infiammazione. *10° Congresso Nazionale del Collegio Italiano di Flebologia*. 17-20 settembre 2006. Siena.

56. Giovagnini L, Sitran S, Caparrotta L, **Montopoli M**, Fregona D. CU(II) and ZN(II)-based potential antitumor agents with sulfur chelating ligands. *XX Congresso Nazionale della Società Chimica Italiana*. 10-15 settembre 2006. Firenze.
57. Giovagnini L, Sitran S, Caparrotta L, **Montopoli M**, Fregona D. Cu(II) potential antitumor agents with sulfur chelating agents. 37th International Conference on Coordination Chemistry. August 13-18, 2006, Cape Town, South Africa.
58. Bellanda M, **Montopoli M**, Lonardoni F, Caparrotta L, Mammi S. ¹H NMR reveals significantly different levels of glutathione in sensitive or spontaneously resistant to cisplatin cells from human ovarian cancer lines. *XXII International Conference on Magnetic Resonance in Biological Systems*. August 20-25, 2006, Göttingen, Germany.
59. Frolidi G, **Montopoli M**, Ragazzi E, Gaion RM, Caparrotta L, Dorigo P. Is in vitro vasorelaxation by ticlopidine related to P2Y₁₂ receptors ? *8th International Symposium on Adenosine and Adenine Nucleotides*. May 24-28, 2006. Ferrara.
60. **Montopoli M**, Ragazzi E, Caparrotta L, Frolidi G. Ticlopidine and clopidogrel affect vascular smooth muscle cell proliferation in culture. *8th International Symposium on Adenosine and Adenine nucleotides*, May 24-28, 2006. Ferrara.
61. Bellanda M, **Montopoli M**, Lonardoni F, Caparrotta L, Mammi S. ¹H-NMR study of sensitive or spontaneously resistant to cisplatin cells from human ovarian cancer lines. *XXXV National Congress on Magnetic Resonance*, August 31 - September 3 2005, Monte Porzio Catone (Roma).
62. **Montopoli M**, Frolidi G, Ragazzi E, Bellanda M, Mammi S, Caparrotta L. ¹H-NMR Spectroscopy and cytotoxicity of natural phenolic compounds on human wild and cisplatin resistant cancer cell. *XXXII° Congresso Nazionale della Società Italiana di Farmacologia*. 1-4 giugno 2005, Napoli.
63. **Montopoli M**, Frolidi G, Comelli MC, Prosdoci M, Caparrotta L. Effect of b-aescin on vascular endothelial cell exposed to cobalt chloride, a model of experimental hypoxia. *XXXII° Congresso Nazionale della Società Italiana di Farmacologia*. 1-4 giugno 2005, Napoli.
64. Frolidi G, Franceschi A, **Montopoli M**, Ragazzi E, Gaion RM, Giron MC, Dorigo P, Caparrotta L. Actions of ticlopidine and clopidogrel on resistance vessel. *XXXII° Congresso Nazionale della Società Italiana di Farmacologia*. 1-4 giugno 2005, Napoli.
65. **Montopoli M**, Frolidi G, Ragazzi E, Caparrotta L. Studies on wild type and CDDP resistant A431 cells lines: ¹H-NMR spectroscopy and effect of natural phenolic compounds. *VIII Seminario Nazionale Dottorandi in Farmacologia ed affini*. 20-23 settembre 2004, Pontignano (Siena).